Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 3-armed trial	24 treatment-resistant people	Change from baseline in Simpson-Angus Scale score 12 weeks –1.64 with quetiapine (mean dose 463.6 mg/day) –0.69 with fluphenazine (mean dose 13.2 mg/day)	P greater-than or equal to 0.05		Not significant
RCT 3-armed trial	24 treatment-resistant people	Change from baseline in weight (kg) 12 weeks –1.2 kg with quetiapine (mean dose 463.6 mg/day) –2.6 kg with fluphenazine (mean dose 13.2 mg/day)	P greater-than or equal to 0.05		Not significant
RCT 3-armed trial	24 treatment-resistant people	Incidence of dyspepsia 8% with quetiapine (mean dose 463.6 mg/day) 23% with fluphenazine (mean dose 13.2 mg/day) Absolute numbers not reported	P >0.05		Not significant
RCT 3-armed trial	24 treatment-resistant people	Incidence of somnolence 25% with quetiapine (mean dose 463.6 mg/day) 33% with fluphenazine (mean dose 13.2 mg/day) Absolute numbers not reported	P >0.05		Not significant
RCT 3-armed trial	24 treatment-resistant people	Incidence of insomnia 25% with quetiapine (mean dose 463.6 mg/day) 42% with fluphenazine (mean dose 13.2 mg/day) Absolute numbers not reported	P >0.05		Not significant